GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) mimic this hormone to slow gastric emptying, reducing appetite and curbing food cravings
Start your personalized treatment plan today.
Injections or pills
Orforglipron (LY3502970), a novel, oral nonpeptide glucagonlike peptide1 receptor agonist: A Phase 1a, blinded, placebocontrolled, randomized, singleand multipleascendingdose study in healthy participants
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study
For example, in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D), weekly subcutaneous Semaglutide (2.4 mg) reduced the risk of major adverse cardiovascular events (MACE heart attack, stroke, or cardiovascular death) by 20% compared to placebo (HR 0.80